A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
received:
06
04
2022
revised:
06
06
2022
accepted:
24
08
2022
pubmed:
30
8
2022
medline:
3
11
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
To assess the contributions of circulating metabolites for improving upon the performance of the risk of ovarian malignancy algorithm (ROMA) for risk prediction of ovarian cancer among women with ovarian cysts. Metabolomic profiling was performed on an initial set of sera from 101 serous and nonserous ovarian cancer cases and 134 individuals with benign pelvic masses (BPM). Using a deep learning model, a panel consisting of seven cancer-related metabolites [diacetylspermine, diacetylspermidine, N-(3-acetamidopropyl)pyrrolidin-2-one, N-acetylneuraminate, N-acetyl-mannosamine, N-acetyl-lactosamine, and hydroxyisobutyric acid] was developed for distinguishing early-stage ovarian cancer from BPM. The performance of the metabolite panel was evaluated in an independent set of sera from 118 ovarian cancer cases and 56 subjects with BPM. The contributions of the panel for improving upon the performance of ROMA were further assessed. A 7-marker metabolite panel (7MetP) developed in the training set yielded an AUC of 0.86 [95% confidence interval (CI): 0.76-0.95] for early-stage ovarian cancer in the independent test set. The 7MetP+ROMA model had an AUC of 0.93 (95% CI: 0.84-0.98) for early-stage ovarian cancer in the test set, which was improved compared with ROMA alone [0.91 (95% CI: 0.84-0.98); likelihood ratio test P: 0.03]. In the entire specimen set, the combined 7MetP+ROMA model yielded a higher positive predictive value (0.68 vs. 0.52; one-sided P < 0.001) with improved specificity (0.89 vs. 0.78; one-sided P < 0.001) for early-stage ovarian cancer compared with ROMA alone. A blood-based metabolite panel was developed that demonstrates independent predictive ability and complements ROMA for distinguishing early-stage ovarian cancer from benign disease to better inform clinical decision making.
Identifiants
pubmed: 36037307
pii: 708818
doi: 10.1158/1078-0432.CCR-22-1113
pmc: PMC9633421
mid: NIHMS1834140
doi:
Substances chimiques
CA-125 Antigen
0
WAP Four-Disulfide Core Domain Protein 2
0
Proteins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4669-4676Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA140388
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217685
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA200462
Pays : United States
Informations de copyright
©2022 American Association for Cancer Research.
Références
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Int J Gynecol Cancer. 2017 Sep;27(7):1360-1366
pubmed: 28604456
J Natl Cancer Inst. 2019 Apr 1;111(4):372-379
pubmed: 30137376
Hum Reprod. 1989 Jan;4(1):1-12
pubmed: 2651469
Tumour Biol. 2014 Jul;35(7):7249-58
pubmed: 24771264
Gynecol Oncol. 1994 Dec;55(3 Pt 2):S42-6
pubmed: 7835810
Cancer. 2013 Oct 1;119(19):3454-61
pubmed: 23983047
Int J Neural Syst. 1997 Apr;8(2):209-18
pubmed: 9327276
J Biol Chem. 2021 Jan-Jun;296:100110
pubmed: 33229435
J Natl Cancer Inst. 2020 Jun 1;112(6):607-616
pubmed: 31503278
Nat Commun. 2020 Aug 27;11(1):4279
pubmed: 32855410
Gynecol Oncol. 2002 Jan;84(1):36-42
pubmed: 11748973
Gynecol Oncol. 2009 Jan;112(1):40-6
pubmed: 18851871
Diagnostics (Basel). 2017 Mar 08;7(1):
pubmed: 28282875
Cancers (Basel). 2021 Feb 22;13(4):
pubmed: 33671595
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Front Oncol. 2020 Mar 31;10:401
pubmed: 32296639
Clin Cancer Res. 2017 Oct 1;23(19):5912-5922
pubmed: 28637689
Science. 2020 Apr 10;368(6487):
pubmed: 32273439
N Engl J Med. 1983 Oct 13;309(15):883-7
pubmed: 6310399
J Ovarian Res. 2019 Mar 27;12(1):28
pubmed: 30917847
Br J Cancer. 2021 Jan;124(1):76-90
pubmed: 33144696
Sci Rep. 2016 Mar 23;6:23642
pubmed: 27004849
Medicines (Basel). 2019 Oct 13;6(4):
pubmed: 31614918
Cancer Res. 2016 Feb 15;76(4):796-804
pubmed: 26685161
Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11
pubmed: 26970494
Cancer. 2020 Feb 15;126(4):725-736
pubmed: 31714597
Nat Cell Biol. 2015 Apr;17(4):351-9
pubmed: 25774832
J Bacteriol. 1985 Nov;164(2):854-60
pubmed: 3902800
Gynecol Oncol. 2013 Feb;128(2):252-9
pubmed: 23178277
Cancer Res. 2018 Jul 1;78(13):3574-3588
pubmed: 29703719
Am J Obstet Gynecol. 2005 Nov;193(5):1630-9
pubmed: 16260202
Asian Pac J Cancer Prev. 2014;15(24):10875-8
pubmed: 25605193
Obstet Gynecol. 2013 Aug;122(2 Pt 1):210-217
pubmed: 23969786
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Obstet Gynecol. 2011 Jun;117(6):1289-1297
pubmed: 21606739
J Bacteriol. 2009 Jun;191(11):3629-38
pubmed: 19304853
Glycoconj J. 2018 Apr;35(2):139-160
pubmed: 29680984